Clinical Trial Update: Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating four transdermal doses of rotigotine for idiopathic restless legs syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• Neupro (rotigotine)

Snippet

Sponsor: UCB Pharma | Conditions: Restless Legs Syndrome | Phase 3 | Status: COMPLETED